phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Gut, Airway and Tumor Microbes Emerge as Promising Predictors of Immunotherapy Response in Lung Cancer

Only 20% to 40% of patients with non small cell lung cancer (NSCLC) respond to immune checkpoint inhibitors, leaving the majority without meaningful clinical benefit. Current biomarkers such as programmed death ligand 1 (PD L1) expression and tumor mutational burden have limited predictive accuracy.

September 9, 2026


September 21 2026

September 18 2026

September 17 2026

September 16 2026

September 15 2026

September 14 2026

September 11 2026

September 10 2026

September 9 2026

September 8 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy